$DNLI News

JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195M

Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data

Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40

Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target

Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $23

Denali Therapeutics Q1 EPS $(0.69) Beats $(0.71) Estimate

Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $34

Denali Therapeutics shares are trading higher after the company announced it secured $200 million in gross proceeds under the Royalty Agreement.

Denali Therapeutics shares are trading higher after the company announced it secured $200 million in gross proceeds under the Royalty Agreement.

Denali Therapeutics Secures $200M Royalty Funding Following U.S. FDA Accelerated Approval Of Tividenofusp Alfa

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow

Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42

Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40

Stifel Maintains Buy on Denali Therapeutics, Raises Price Target to $41

Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $32